699854P
4A-MPLA (isomer C3)
Manufacturer: Sigma Aldrich
CAS Number: 2260669-09-6
Synonym(S): Monophosphopdyl Tetra-acyl Lipid A
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 1 MG | 699854P-1-MG | In Stock | ₹ 1,13,976.43 |
699854P - 1 MG
In Stock
Quantity
1
Base Price: ₹ 1,13,976.43
GST (18%): ₹ 20,515.757
Total Price: ₹ 1,34,492.187
Assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699854P-1mg)pkg of 1 × 5 mg (699854P-5mg)
manufacturer/tradename
Avanti Polar Lipids
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2OC(C[C@H](O)CCCCCCCCCCC)=O.[NH4+]
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
 | 2260669-09-6 | Monophosphoryl Tetra-acyl Lipid A | A2B Chem | ₹ 2,74,219.80 |
Related Products
Description
- Biochem/physiol Actions: Structural modification of diphosphoryl lipid A by hydrolysis produces MPLA (monophosphoryl lipid A) and is known to decrease its toxicity. MPLA, a lipopolysaccharide derivative, acts an immunomodulator and is non-toxic. For this reason, it is useful as a vaccine adjuvant. The MPLA induced immune response is tissue specific.[1] It enhances host′s resistance against endotoxin induced effects. It also decreases cytokine production during infection.[2]
- Packaging: 2 mL Amber Glass Crimp Cap Vial (699854P-1mg)
- Other Notes: For R&D use only. Not for drug, household, or other uses.
SAFETY INFORMATION
WGK
WGK 3
Compare Similar Items
Show Difference
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699854P-1mg)pkg of 1 × 5 mg (699854P-5mg)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2OC(C[C@H](O)CCCCCCCCCCC)=O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699854P-1mg)pkg of 1 × 5 mg (699854P-5mg)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2OC(C[C@H](O)CCCCCCCCCCC)=O.[NH4+]
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay: ≥99% (TLC)
form: powder
packaging: pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: [Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC
Assay:
≥99% (TLC)
form:
powder
packaging:
pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
[Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC
Assay: ≥99% (TLC)
form: powder
packaging: pkg of 1 × 10 mg (699857P-10MG)pkg of 1 × 5 mg (699857P-5MG)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: [Na+].CCCCCCCCCCCC(=O)NC1C(OC(=O)CCCCCCCCCCC)OC(CO)C(OP(O)([O-])=O)C1OC(=O)CCCCCCCCCCC
Assay:
≥99% (TLC)
form:
powder
packaging:
pkg of 1 × 10 mg (699857P-10MG)pkg of 1 × 5 mg (699857P-5MG)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
[Na+].CCCCCCCCCCCC(=O)NC1C(OC(=O)CCCCCCCCCCC)OC(CO)C(OP(O)([O-])=O)C1OC(=O)CCCCCCCCCCC